CORONAVIRUS: DIAGNÓSTICO Y TERAPIA EN HUMANOS

VolverVolver

Resultados 474 resultados LastUpdate Última actualización 29/11/2022 [16:22:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 60 días/Published applications in the last 60 days



previousPage Página2 de 19 nextPage   por página


BRET-BASED CORONAVIRUS MPRO PROTEASE SENSOR AND USES THEREOF

NºPublicación: WO2022245231A2 24/11/2022

Solicitante:

QATAR FOUND EDUCATION SCIENCE & COMMUNITY DEV [QA]

Resumen de: WO2022245231A2

The SARS-CoV-2 main protease, MPRO, is critical for its replication and is an appealing target for designing anti-SARS-CoV-2 agents. In this regard, a number of assays have been developed based on its cleavage sequence preferences to monitor its activity. These include the usage of Fluorescence Resonance Energy Transfer (FRET)-based substrates in vitro and a FlipGFP reporter, one which fluoresces after MPRO-mediated cleavage, in live cells. Here, a pair of genetically encoded, Bioluminescence Resonance Energy Transfer (BRET)-based sensors have been engineered for detecting SARS-CoV-2 MPRO proteolytic activity in living host cells. The sensors were generated by sandwiching MPRO N-terminal autocleavage sites, either AVLQSGFR (short) or KTSAVLQSGFRKME (long), in between the mNeonGreen and nanoLuc proteins. Co-expression of the sensor with the MPRO in live cells resulted in its cleavage in a dose-dependent manner while mutation of the critical C145 residue (C145A) in MPRO completely abrogated the sensor cleavage. A temporal activity of MPRO in live cells and its inhibition was shown using the well-characterized pharmacological agent GC376. The sensor developed here finds direct utility in studies related to drug discovery targeting the SARS-CoV-2 MPRO and functional genomics application to determine the effect of sequence variation in MPRO. Importantly, the BRET-based sensors displayed increased sensitivities and specificities as compared to the recently developed FlipGFP-based M

traducir

NANO ANTIBODY FOR NEUTRALIZING TOXICITY OF SARS-COV-2 AND PREPARATION METHOD AND APPLICATION THEREOF

NºPublicación: US2022372113A1 24/11/2022

Solicitante:

SYSVAX INC [CN]

WO_2022048052_A1

Resumen de: US2022372113A1

The present disclosure discloses a nano antibody for neutralizing a toxicity of SARS-CoV-2 and preparation method thereof. The nano antibody comprises a complementarity determining region CDR comprising a CDR1, a CDR2 and a CDR3; an amino acid sequence of the CDR1 is selected from at least one of amino acid sequences shown in SEQ ID NO.1 and SEQ ID NO.2; an amino acid sequence of the CDR2 is selected from at least one of amino acid sequences shown in SEQ ID NO.3, SEQ ID NO.4, and SEQ ID NO.5; and an amino acid sequence of the CDR3 is selected from at least one of amino acid sequences shown in any one of SEQ ID NO.6 to SEQ ID NO.9. The nano antibody for neutralizing the toxicity of SARS-CoV-2 has the advantages of a small molecular weight, a high affinity with the SARS-CoV-2, a low production cost, and the like.

traducir

METHODS OF OBTAINING AND USING ELECTROCHEMICAL DIAGNOSTIC RESULTS

NºPublicación: US2022373510A1 24/11/2022

Solicitante:

PERSOWN INC [US]

US_2022373498_PA

Resumen de: US2022373510A1

Methods and techniques are described for analyzing test fluids to determine presence, absence, or concentration of analytes in the test fluids. The methods may correspond to diagnostic testing, such as quickly (within 5 minutes) identifying whether or not an individual may have a particular disease or condition, such as infection by SARS-CoV-2 or a SARS-CoV-2 variant or vaccine-induced immunity or natural immunity to infection by SARS-CoV-2 or a SARS-CoV-2 variant, or whether an individual would benefit from a vaccine booster. The test results can be used for a variety of applications including facilitating or controlling access at events, venues, or transportation systems, or generating exposure notifications.

traducir

ELECTROCHEMICAL DIAGNOSTIC SYSTEM

NºPublicación: US2022373498A1 24/11/2022

Solicitante:

PERSOWN INC [US]

US_2022373510_PA

Resumen de: US2022373498A1

Described are devices, systems, kits, methods, and techniques for analyzing test fluids to determine presence, absence, or concentration of analytes in the test fluids and useful for performing diagnostic testing, such as to quickly identify whether or not an individual may have a particular disease or condition, such as infection by SARS-CoV-2 or a SARS-CoV-2 variant or vaccine-induced immunity or natural immunity to infection by SARS-CoV-2 or a SARS-CoV-2 variant. The devices, systems, kits, methods, and techniques described herein can be used to detect analytes in body fluids using a functionalized electrochemical test strip and potentiostatic measurements, allowing for prompt identification of whether or not an individual has a particular disease or condition, such as in a period of 5 minutes or less.

traducir

ANTIBODY CONJUGATED NANOPARTICLE ASSAY AND TREATMENT FOR SARS-CoV-2

NºPublicación: US2022370958A1 24/11/2022

Solicitante:

ARIZONA BOARD OF REGENTS ON BEHALF A ARIZONA STATE UNIV [US]
HALBERD CORP [US]

Resumen de: US2022370958A1

An embodiment provides a method for treatment of a viral antigen for the COVID-19 virus, including: obtaining a body fluid from a patient; introducing the body fluid to at least one binding antibody, wherein the at least one binding antibody binds to an antigen of the SARS-CoV-2 spike (S) protein and comprises a conjugated metal; forming a viral antigen-antibody complex; and removing the viral antigen-antibody complex from the body fluid using a radiofrequency method; and returning the body fluid to the patient. Other aspects are described and claimed.

traducir

COVID-19 EXPOSURE DETECTOR

NºPublicación: US2022369733A1 24/11/2022

Solicitante:

ZORE TERRY [US]

Resumen de: US2022369733A1

The disclosure is the only product of its kind with the potential to curb the spread of contagious aerosolized disease via widely accessible and versatile disc that complements the requirement for wearing a face mask. CODIS is uniquely designed to enhance the contact tracing process of infectious diseases and serves as a proactive medium for identifying disease exposure in real-time. The disclosed pathogen indicator device includes a reagent configured to trigger a chemical reaction based on an exposure to a predetermined pathogen. The disclosure also includes a mask substrate configured to receive the reagent on a front side and to bond therewith on a backside thereof. The disclosure further includes a seal for the substrate and the reagent, the seal configured to provide a prophylactic temporary protection from the predetermined pathogen.

traducir

METHODS FOR TREATING POST INFECTIOUS AUTOIMMUNE DIABETES

NºPublicación: US2022372146A1 24/11/2022

Solicitante:

PROVENTION BIO INC [US]

Resumen de: US2022372146A1

Provided herein are a method of treating type 1 diabetes (T1D) post SARS-CoV-2 infection. In some embodiments, such method can include administering to a subject in need thereof a 12-day course of teplizumab at a total dose of more than about 9000 μg/m2.

traducir

SARS-COV-2 RECOMBINANT N PROTEIN, AND PREPARATION METHOD AND PURIFICATION METHOD THEREFOR

NºPublicación: US2022372083A1 24/11/2022

Solicitante:

SHENZHEN YHLO BIOTECH CO LTD [CN]

WO_2021169433_A1

Resumen de: US2022372083A1

Provided are a recombinant N protein of SARS-CoV-2 and methods for preparing the same and for purifying the same. The recombinant N protein of SARS-CoV-2 has an N protein sequence, wherein each of both ends of the N protein sequence are linked to an oligolysine fragment. An expression method for the recombinant N protein includes: a. providing a sample including the recombinant N protein; and b. performing cation exchange chromatography resin purification treatment at least once, and collecting breakthrough substance. The method may effectively improve the expression purity of the recombinant N protein.

traducir

COMPOSITIONS AND METHODS FOR TREATING SARS-COV-2 INFECTIONS

NºPublicación: US2022372082A1 24/11/2022

Solicitante:

NFERENCE INC [US]

WO_2022235567_PA

Resumen de: US2022372082A1

This application relates to methods for treating or reducing viral infection in a human subject, comprising administering to the subject a pharmaceutical composition comprising a protease inhibitor.

traducir

SARS-COV-2 SUBUNIT AND VARIANT VACCINES

NºPublicación: US2022372080A1 24/11/2022

Solicitante:

IBIO INC [US]

WO_2022226201_PA

Resumen de: US2022372080A1

The present invention includes an immunogenic protein, constructs, vectors, and methods of making, comprising at least 90% amino acid identity to at least one antigenic peptide selected from: a coronavirus Receptor Binding Domain (RBD), coronavirus a Receptor Binding Motif (RBM) of a coronavirus spike protein, a coronavirus spike protein N-terminus, a nucleocapsid protein, one or more T cell epitopes from a coronavirus spike protein, or one or more T cell epitopes from a coronavirus nucleocapsid protein, or combination thereof. In one example, the at least one antigenic peptide is positioned at, at least one of, the N-terminus, the C-terminus, or in a loop region of the carrier protein or peptide tag.

traducir

Tennis Balls Sanitizing Machine

NºPublicación: US2022370664A1 24/11/2022

Solicitante:

SINGH SHASHWAT [US]

Resumen de: US2022370664A1

COVID-19 and many other infectious diseases like Flu can spread through by touch. Tennis player exchange the same balls multiple times during the practice or game. For student's safety schools and colleges currently sanitize the balls manually which is a tedious and time taking job. This invention sanitizes the bunch of tennis balls in one go with the push of a buttons and a Knob which control the speed of motor vibration.

traducir

ANTIVIRAL ESSENTIAL OIL COMPOSITIONS

NºPublicación: US2022370535A1 24/11/2022

Solicitante:

ERDOGMUS HUESEYIN [KR]

WO_2022093141_A1

Resumen de: US2022370535A1

Disclosed are antiviral essential oil compositions including one or more essential oils, such as styrax oil and resinoid, gurjun balsam oil, olibanum resinoid, nootka tree oil, vetiver oil, jatamansi oil, sandalwood oil, myrrhe oil, agarwood oil, copaiba balsam oil, ginger oil, curcuma oil, clary sage absolute, cypriol oil, rosemary oil, eucalyptus globulus, tea tree oil, patchouly oil, benzyl benzoate, vertofix(acetylated cedarwood oil), benzyl salicylate, benzyl cinnamate, cinnamyl benzoate, cinnamyl cinnamate, dihydroambrettolide, galaxolide, L-muscone, nootkatone, vetiveryl acetate, sclareol. The use of discovered fragrance molecules and essential oils alone or combination provides beneficial antiviral effects, especially for SARS-CoV-2 (COVID-19).

traducir

MESSENGER RNA THERAPEUTICS AND COMPOSITIONS

NºPublicación: US2022370599A1 24/11/2022

Solicitante:

GREENLIGHT BIOSCIENCES INC [US]

Resumen de: US2022370599A1

In the various aspects and embodiments, this disclosure provides messenger RNA (mRNA) constructs for therapeutic delivery, as well as methods for making such mRNA constructs and pharmaceutical compositions comprising the same (including mRNA vaccine compositions). In still other aspects, the invention provides methods for treating patients by expression of therapeutic proteins, including for preventing or reducing probability of infection by, or illness involving, a virus. Exemplary viruses include coronaviruses (such as SARS-CoV-2 and variants therefore) and influenza viruses, among others.

traducir

SARS-CoV-2 POLYPEPTIDES

NºPublicación: US2022370601A1 24/11/2022

Solicitante:

MAYO FOUND MEDICAL EDUCATION & RES [US]

Resumen de: US2022370601A1

This document provides methods and materials related to selected severe acute respiratory distress coronavirus 2 (SARS-CoV-2) polypeptides. For example, this document provides vaccine compositions that contain one or more selected SARS-CoV-2 polypeptides provided herein and that have the ability to induce or increase immune responses against coronaviruses such as SARS-CoV-2 within a mammal (e.g., a human).

traducir

METHODS FOR TREATING, AMELIORATING OR PREVENTING INFECTIONS USING DRUG AND VACCINATION COMBINATION TREATMENT

NºPublicación: US2022370589A1 24/11/2022

Solicitante:

TOPELIA AUSTRALIA PTY LTD ACN 652 771 670 [AU]

Resumen de: US2022370589A1

In alternative embodiments, provided are methods for treating, ameliorating, decreasing the chances of having any adverse effects from, decreasing the severity of adverse effects from, or preventing an infection by administration of an antibiotic and/or an anti-viral drugs and a vaccine directed to a causative agent of the infection and/or an attenuated and/or a live, viable or infectious causative agent of the infection. In alternative embodiments, the infection is bacterial or viral. In alternative embodiments, the viral infection is a coronavirus infection such a Covid-19 infection. In alternative embodiments, methods as provide herein prevent or decrease the prevalence or severity of “vaccine breakthrough infections” after vaccination, where external mutants of COVID-19 infect patients in spite of the fact that they have undergone immunization, for example, to prevent a mutant or variant COVID-19 infection. In alternative embodiments, an antiviral combination administered in coordination with a vaccine comprises PF-07321332 or PAXLOVID™ and/or ritonavir, or ivermectin, doxycycline and a zinc or a zinc salt. In alternative embodiments, methods as provided herein are used to prevent in vivo mutations of such mutant infectious agent to enhance the efficacy of an administered vaccination; in other words, methods as provided herein are used to prevent in vivo replication of an acquired viral mutant or variant infectious agent, and thus also prevents ongoing mutations of

traducir

SARS-COV-2 POLYPEPTIDES

NºPublicación: WO2022246084A1 24/11/2022

Solicitante:

MAYO FOUND MEDICAL EDUCATION & RES [US]

US_2022370601_A1

Resumen de: WO2022246084A1

This document provides methods and materials related to selected severe acute respiratory distress coronavirus 2 (SARS-CoV-2) polypeptides. For example, this document provides vaccine compositions that contain one or more selected SARS-CoV-2 polypeptides provided herein and that have the ability to induce or increase immune responses against coronaviruses such as SARS-CoV-2 within a mammal (e.g., a human).

traducir

ELECTROCHEMICAL DIAGNOSTIC SYSTEM AND METHODS OF OBTAINING AND USING ELECTROCHEMICAL DIAGNOSTIC RESULTS

NºPublicación: WO2022246292A1 24/11/2022

Solicitante:

PERSOWN INC [US]

Resumen de: WO2022246292A1

Devices, systems, kits, methods, and techniques are described herein that are useful for to detecting analytes in body or test fluids using a functionalized electrochemical test strip and potentiostatic measurements, allowing for quickly (within 5 minutes) identifying whether or not an individual has a particular disease or condition, such as infection by SARS-CoV-2 or a variant or vaccine-induced immunity or natural immunity to infection by SARS-CoV-2 or a variant, or whether an individual would benefit from a vaccine booster. The test results can be used for applications including facilitating or controlling access at events, venues, or transportation systems, or generating exposure notifications. The electrodes include a SAM linked to the capture agents via a click chemistry based linker. There's also a charged passivation component (e.g. thiolated PEG) in the SAM. Charged glycosaminoglycans in the SAM contribute to anti-fouling and improving the sensitivity of the device.

traducir

ASSAYS FOR VIRAL STRAIN DETERMINATION

NºPublicación: WO2022246213A1 24/11/2022

Solicitante:

MESO SCALE TECHOLOGIES LLC [US]
US HEALTH [US]

Resumen de: WO2022246213A1

The invention relates to methods and kits for determining a SARS-CoV-2 strain in a sample. The invention also provides methods and kits for detecting a single nucleotide polymorphism (SNP) in a target nucleic acid, wherein the target nucleic acid is a SARS-CoV-2 nucleic acid. The inventor further provides methods and kits for detecting one or more antibody biomarkers in a sample.

traducir

SARS-COV-2 SPIKE PROTEIN ANTIBODIES

NºPublicación: WO2022245877A1 24/11/2022

Solicitante:

CURIA IP HOLDINGS LLC [US]

Resumen de: WO2022245877A1

Embodiments include monoclonal antibodies (mAbs) that recognize SARS-Cov-2 spike protein. The mAbs are capable of distinguishing among variants of the virus. The present disclosure also provides a composition and methods of making and using such a composition for treating, preventing, and/or detecting SARS-CoV-2 infection.

traducir

SARS-COV-2 SPIKE PROTEIN ANTIBODIES

NºPublicación: WO2022245859A1 24/11/2022

Solicitante:

CURIA IP HOLDINGS LLC [US]

US_2022372114_PA

Resumen de: WO2022245859A1

The present disclosure provides antibodies that bind to the SARS-CoV-2 spike protein, as well as compositions containing the same, and methods of making and using such a composition for treating, preventing, and/or detecting SARS-CoV-2 infection.

traducir

CORONAVIRUS VACCINE SUITABLE FOR ELDERLY INDIVIDUALS

NºPublicación: WO2022244831A1 24/11/2022

Solicitante:

OKINAWA INST SCIENCE & TECH SCHOOL CORP [JP]

Resumen de: WO2022244831A1

The present invention provides a vaccine or an immunogenic composition that can be useful in an elderly human subject.

traducir

METHODS AND REAGENTS OF IMMUNOLOGICALLY DETECTING SARS-CoV-2

NºPublicación: US2022373546A1 24/11/2022

Solicitante:

FUJIREBIO KK [JP]

Resumen de: US2022373546A1

The present invention provides a method of immunologically detecting SARS-CoV-2, the method comprising detecting a SARS-CoV-2 N protein in a specimen taken from a subject by using the following antibodies (1) and (2): (1) a first antibody to a first epitope in a 306th to 339th amino acid region in the SARS-CoV-2 N protein, and (2) a second antibody to a second epitope in a 365th to 419th amino acid region in the SARS-CoV-2 N protein.

traducir

BLOOD COLLECTION STRUCTURE, AND WHOLE BLOOD AND FINGERSTICK BLOOD DETECTION DEVICE AND METHOD

NºPublicación: EP4092412A1 23/11/2022

Solicitante:

ASSURE TECH HANGZHOU CO LTD [CN]

US_2022323950_PA

Resumen de: EP4092412A1

The present invention relates to a whole blood and fingertip blood testing device, including a blood collection structure and a testing chamber connected to and in fluid communication with the blood collection structure. The blood collection structure includes a collection rod, a capillary channel is arranged inside the collection rod, the bottom end of the capillary channel is located at the tail end of the collection rod, and the top end of the capillary channel is located in the middle of the capillary channel; and the collection rod is provided with a communicating hole connected to and communicated with the top end of the capillary channel. Moreover, the present invention also provides a method for collecting and testing a blood sample by using the testing device. Through the integrated structure of the blood collection structure, the testing chamber and the buffer chamber, the whole blood and fingertip blood testing device and method achieve functions of collecting, slowly releasing and testing the blood sample. The operation is easy, which reduces the difficulty of use by the operator. The number of times and time that the operator contacts the sample are effectively reduced, and the infectious possibility of the operator is reduced, so that the testing device is suitable for HIV testing, novel coronavirus testing, etc. The testing device and method have low requirements on the collected amount of the sample, and the collected amount is optimized from the milliliter le

traducir

Fusion protein

NºPublicación: GB2606693A 23/11/2022

Solicitante:

EXOSIS INC [US]

WO_2022216949_PA

Resumen de: GB2606693A

The fusion protein comprises a tetraspanin exosomal protein and one or more immunogenic proteins. The tetraspanin may be CD63, CD9 or CD81, or a fragment or variant thereof. The protein may be capable of eliciting an immune response against a SARS-CoV-2 protein, such as the spike protein. Also claimed is an exosome or membrane preparation comprising the fusion protein, a vaccine composition comprising the exosome or membrane preparation, a nucleic acid molecule, an expression vector and a cell comprising the fusion protein. Also claimed is a method of preventing or ameliorating an infection comprising providing the subject with a therapeutically effective amount of the exosome, membrane preparation or vaccine composition. The exosome may comprise a DC receptor ligand and/or an immune enhancing moiety.

traducir

Covid Balloon Test

Nº publicación: GB2606751A 23/11/2022

Solicitante:

OLYMPIA LONDON LTD [GB]

Resumen de: GB2606751A

A Covid-19 balloon test comprising the process of testing air blown out by a person and captured in a Covid Balloon test balloon 101 which is sealed and transported to a test centre for testing of Covid-19, SARS, and other medical or non-medical conditions. Additionally, the testing of air blown out by a person is carried out by using a controlled environment machine, or in a laboratory to test for Covid-19, SARS, and other medical or non-medical conditions. The special balloon may comprise any suitable container or box suitable to capture, store and transport the captured breath.

traducir

previousPage Página2 de 19 nextPage por página

punteroimgVolver